INFORMATION OF THE SECOND STATE OF THE SECOND SECON

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

1

OF

2

Docket Number 47508-518 HYZ-030CPCN3 Application Number 09/777,526

Applicant Agrawal, et al.

Filing Date 2/6/2001 Group Art Unit 1635

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,510,239	4/23/96	Baracchini, et al.	ļ		
				_	 	
						-
		y				

EXAMINER	DOCUMENT	DATE	gn Patent Docum	CLASS	SUBCLASS	TRANSLATION	
INIT	NUMBER	DATE	COUNTRY		SUBCLASS	YES	NO
1	WO94/23028	10/13/1994	WO				
	WO96/12497	5/2/1996	WO				
	WO97/11171	3/27/1997	WO				

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
-	A1	Agrawal; "In Vivo Pharmacokinetics of Oligonucleotides"; in Applied Antisense Oligonucleotide Technology (Stein and Krieg, Eds.), pp. 365-385 (1998)
	A2	Agrawal, "Preface", in Methods in Molecular Medicine: Antisense Therapeutics (Agrawal, Ed.); pp. v-vii (1996)
	А3	Agrawal, et al.; "Comparative Pharmacokinetics of Antisense Oligonucleotides"; in Methods in Molecular Medicine: Antisense Therapeutics (Agrawal, Ed.); pp. 247-270 (1996)
	A4	Branch; "A Good Antisense Molecule is Hard to Find"; TIBS 23; pp. 45-50, February 1998
•	A5	Crooke; "Basic Principles of Antisense Therapeutics"; in Antisense Research and Application (Crooke, Ed.); pp. 1-50 (1998)
4	A6	Crystal; "Transfer of Genes to Humans: Early Lessons and Obstacles to Success"; Science; vol. 270, pp. 404-410 (1995)
•	B1	Friedmann; "Overcoming the Obstacles"; Scientific American; pp. 96-101, June 1997

EXAMINER	DATE CONSIDERED					
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw methoding transfer if not conformance and not considered, include convey with part communication to applicant						
if not conformance and not considered. Include conv with next con-	omunication to applicant					

BOSTON 1514336v1

OCT 1 0 2002

TECH CENTER 1600/2900


Subt. For, PTC	ORMATIO	N DISCLO	DSUPPE I P &	Docket Num HYZ-030CP 3	Application Number 09/777,526
	IN AN AP	PLICATION	ON 955211 APR 0 7 20	Appli Appli	
Sheet	1	OF	A ST INCOME	Filing Date	Group Art Unit 1635

U.S. Patent Documents						
EXAMINER JUITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>39</i>	4,309,404	1/5/1982	DeNeale et al.	<u> </u>		
	4,309,406	1/5/1982	Guley et al.			
	4,556,552	12/3/1985	Porter et al.			
	4,704,295	11/3/1987	Porter et al.			
	5,149,797	9/22/1992	Pederson et al.			
	5,220,007	6/15/1993	Pederson et al.			
	5,248,670	9/28/1993	Draper et al.			
	5,271,941	12/21/1993	Cho-Chung			
	5,403,709	4/4/1995	Agrawal et al.			
	5,442,049	8/15/1995	Anderson et al.			
	5,470,967	11/28/1995	Huie et al.			
	5,514,577	5/7/1996	Draper, et al.			
	5,578,716	11/26/1996	Szyf,. et al.			
_	5,612,212	3/18/1997	Gewirtz			
	5,652,355	7/29/1997	Metelev, et al.			
	5,969,117	10/19/1999	Agrawal			
ΨÀ	6,143,881	11/7/2000	Metelev, et al.			

Foreign Patent Documents							
EXAMINER	DOCUMENT		00111/2014	01.400	SUBCLASS	TRANSI	ATION
INITIAL		DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
Py .	92/03568	3/5/1992	WO				
4	93/08296	4/29/1993	WO				
	93/13114	7/8/1993	WO				
-	93/13740	7/22/1993	WO	·			
	93/19203	9/30/1993	WO				
1	94/02498	2/3/1994	WO				
	94/15619	7/21/1994	WO		·		
42	94/19945	9/15/1994	WO				

EXAMINER DUL DO	DATE CONSIDERED 6/26/03				
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.					

BOSTON 1609152v1



Applicants Coon

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number HYZ-030CPCN3 47508-<u>5</u>18

Application Number 09/777,526

Applicant Agrawal

Filing Date **Group Art Unit** OF 1635 Sheet 1 1 2/6/2001

	U.S. Patent Documents					
EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
*XX	5,587,361	12/24/1996	Cook, et al.			
					-	 -
			-		 	
					ļ	
				ļ		
		l		_L		

Foreign Patent Documents							
EXAMINER	DOCUMENT	DOCUMENT	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL	NUMBER	DATE	COUNTRY	CLASS		YES	NO
					1		
				-			
İ							

	Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
A1	
A2	
A3	
A4	
A5	
A6	
B1	
B2	
B3	
B4	
B5	
B6	
B7	
B8	

EXAMINER O	DATE CONSIDERED
Jolla AD	\$100

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

\$110/04

Azglicants Cozan

W C P H AND D LLP

Subl. For, PTO-1449 Docket Number **Application Number** 47508-518 09/777,526 INFORMATION DISCLOSURE HYZ-030CPCN3 IN AN APPLICATION Applicant Agrawal, et al. (Use several sheets if necessary) Filing Date **Group Art Unit** Sheet 1 ÖF 2 2/6/2001 1635

U.S. Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
724	5,510,239	4/23/96	Baracchini, et al.				
	<u></u>						
<u> </u>	<u>.</u>						
					1	· · · · · · · · · · · · · · · · · · ·	
						····-	

EXAMINER		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL						YES	NO
XX	WO94/23028	10/13/1994	WO				1
	WO96/12497	5/2/1996	WO				
1	WO97/11171	3/27/1997	WO				
							Ĺ
					1		1

	•	Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
Let Let	A1	Agrawal; "In Vivo Pharmacokinetics of Oligonucleotides"; in Applied Antisense Oligonucleotide Technology (Stein and Krieg, Eds.), pp. 365-385 (1998)
	A2	Agrawal, "Preface", in Methods in Molecular Medicine: Antisense Therapeutics (Agrawal, Ed.); pp. v-vii (1996)
	A3	Agrawal, et al.; "Comparative Pharmacokinetics of Antisense Oligonucleotides"; in Methods in Molecular Medicine: Antisense Therapeutics (Agrawal, Ed.); pp. 247-270 (1996)
	A4	Branch; "A Good Antisense Molecule is Hard to Find"; TIBS 23; pp. 45-50, February 1998
	AS	Crooke; "Basic Principles of Antisense Therapeutics"; in Antisense Research and Application (Crooke, Ed.); pp. 1-50 (1998)
(Du	Al6	Crystal; "Transfer of Genes to Humans: Early Lessons and Obstacles to Success"; Science; vol. 270, pp. 404-410 (1995)
AN.	_ B1	Friedmann; "Overcoming the Obstacles"; Scientific American; pp. 96-101, June 1997

EXAMINER, (DATE CONSIDERED	
\mathcal{N}	tolar	
	1 4/10/04	
EXAMINED Initial if allotion is considered whether or	and affection to in confirmation with Mitter & complete of the stand	

EXAMINEH: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

BOSTON 1514336v1

	•			<u>,—-;</u>		
Subt. For, PT	0-1449			Docket Number	Application Number	
INIT	ODLAATION I	DICOL	00.105	47508-518	09/777,526	
INP				HYZ-030CPCN3		
}	IN AN APPL	JICA H	אכ	Applicant		
(Use several sheets if necessary)				Agrawa		
				Filing Date	Group Art Unit	
Sheet	2	OF	2	2/6/2001	1635	

29	B2	Monia, et al.; "Antitumor Activity of a Phosphorothioate Antisense Oligodeoxynucleotide Targeted Against C-raf Kinase"; Nature Medicine; Vol. 2, No. 6, pp. 668-675, June 1996
	B3	Schofield et al.; "Non-viral Approaches to Gene Therapy"; British Medical Bulletin; Vol. 51, No. 1, pp. 56-71 (1995)
	В4	Verma, et al.; "Gene Therapy – Promises, Problems, and Prospects"; Nature; Vol. 389, pp. 239-242, September 1997
	B5	Vlassov, et al.; "In Vivo Pharmacokinetics of Oligonucleotides Following Administration by Different Routes"; in <u>Delivery Strategies for Antisense Oligonucleotide Therapeutics</u> (Akhtar, Ed.); pp. 71-83 (1995).
424	B6	Vlassov, et al.; "Penetration of Oligonucleotides into Mouse Organism through Mucosa and Skin"; FEBS Letters; Vol. 327, No. 3, pp. 271-274; August 1993
	B7	
	B8	
	B9	
	B10	
	B11	
	B12	
	B13	
	B14	
	B15	
	C1	·
	C2	
	Ca	
	C4	
	C5	
	C6	
	C7	
	C8	
	C9	
	C10	
	C11	
	C12	
	C13	
<u> </u>	C14	
	C18	
	C16	
	C17	
	D1	
	D2	
	D3	
EYAMINE		DATE CONSIDERED

EXAMINER: thital if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

BOSTON 1514336v1